Novavax's Nuvaxovid XBB.1.5 COVID-19 Vaccine Has Been Granted Emergency Use Listing By The World Health Organization For Active Immunization In Individuals Aged 12 And Older
Portfolio Pulse from Benzinga Newsdesk
The World Health Organization has granted Emergency Use Listing to Novavax's Nuvaxovid XBB.1.5 COVID-19 vaccine for active immunization in individuals aged 12 and older.
November 28, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's Nuvaxovid XBB.1.5 COVID-19 vaccine receives WHO Emergency Use Listing for individuals aged 12+, potentially boosting the company's vaccine adoption and sales.
The WHO's Emergency Use Listing is a significant endorsement that can lead to increased adoption and sales of Novavax's vaccine. This approval may boost investor confidence and could lead to a short-term uptick in Novavax's stock price as the market reacts to the positive regulatory development.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100